Miralinc Pharma

Miralinc Pharma focuses on developing effective drug therapies targeting debilitating diseases of the peripheral and central nervous systems. The company collaborates with leading academic research scientists and experts in human drug development to create cures for patients. Miralinc's research emphasizes the therapeutic potential of HDAC6 inhibitors (HDAC6i) to treat peripheral neuropathies, including Charcot-Marie-Tooth disease (CMT), Diabetic Neuropathy (DN), and Chemotherapy Induced Neuropathy (CIPN). Preclinical studies in transgenic mouse models have shown that inhibiting HDAC6 can reverse neurological disease symptoms and restore nerve function. The company operates in the pharmaceutical market, serving patients with hereditary disorders that damage nerves in the arms and legs. Miralinc's business model involves advancing drug development from research to clinical application, generating revenue through the commercialization of successful therapies.

Keywords: drug therapies, peripheral neuropathies, HDAC6 inhibitors, nerve damage, CMT, DN, CIPN, neurological diseases, pharmaceutical market, patient care.